48 results about "Drug elution" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Covered stents may be coated with or otherwise include a drug eluting composition. An illustrative stent may comprise an elongated tubular body having a strut framework defining a plurality of open cells. A polymeric coating may be disposed on a surface of the elongated tubular body and extending across the plurality of open cells and a first drug coating composition disposed on a surface of the polymeric coating.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum, and a drug-eluting biodegradable material that biodegrades over time to release a drug that limits tissue overgrowth. The inventive device also may include a biodegradable material that biodegrades to offset flow changes caused by tissue overgrowth. The inventive device may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits.

DRUG ELUTING OCULAR IMPLANT

An electronic system for multimodal diagnostic measurements and therapeutic interventions includes a plurality of element network layers vertically stacked one with another on a flexible substrate, each element network layer being bi-axially stretchable and comprising a plurality of elements configured in an addressable, interconnected array formed in a multilayered structure and operably performing a distinct function. The electronic system is a multimodal, multiplexed soft electronic system in a multilayered configuration that supports capabilities ranging from high-density spatiotemporal mapping of temperature, pressure and electrophysiological parameters, to options in programmable high-density actuation of thermal inputs and / or electrical stimulation, drug elution, radio frequency ablation, and / or irreversible electroporation ablation.

The disclosed concept includes the use of additive and / or subtractive manufacturing of mesoporous structures on two-dimensional sheets that are mechanically tunable, to provide a vascular graft that controls biodegradable graft host interactions, to improve graft patency and functionality long-term. The vascular graft includes the two-dimensional sheets in a rolled or tubular configuration to form a lumen wherein a surface and / or bulk modification is applied to the flat sheet. In addition, a plurality of mesoporous structures (e.g., gaps) are formed in the flat sheet using a subtractive manufacturing technique.

The present disclosure provides a method for preventing blood coagulation, comprising administering an effective amount of ginsenoside compound K (CK) to a subject in need thereof. The present disclosure also provides a use of ginsenoside compound K (CK) in the manufacture of a medicament for preventing blood coagulation. The present disclosure further provides a drug-eluting percutaneous coronary intervention (PCI) device comprising a vascular implant, the surface of which is coated with a first layer comprising ginsenoside compound K (CK) and a first bioabsorbable polymer, the first bioabsorbable polymer comprising poly-L-lactic acid (PLLA) and poly(L-lactide-co-ε-caprolactone) (PLCL) in a mass ratio of 60%-80%:20%-40%.

The application discloses a shock wave balloon catheter and belongs to the technical field of medical devices, which comprises a tube body, a balloon arranged on the outer wall of the tube body, at least one shock wave generator arranged in the balloon, and a convex device arranged on the outer surface of the balloon, wherein the convex device and the outer surface of the balloon are provided with a drug coating, at least one liquid injection cavity and a guide wire cavity are arranged in the tube body, and the liquid injection cavity is communicated with the balloon; the application integrates multi-form mechanical convex devices on the surface of the balloon, and coats anti-proliferation drugs on the surface of the convex device and the balloon, so that the trinity treatment of mechanical cutting / piercing, shock wave and drug elution is realized, the three functions of mechanical fragmentation of calcification / fibrosis lesions, shock wave deep lysis of calcified substances and local drug delivery are simultaneously achieved by the same instrument, one-time comprehensive treatment of complex vascular lesions is realized, and instrument replacement is avoided.

Various exemplary devices and methods are provided for performing surgical procedures. In general, one or more adjuncts can be used in conjunction with surgical instruments. The adjunct(s) can have medicant(s) thereon and / or therein. The medicant(s) can vary depending on the desired effect of the medicant(s) on surrounding tissue. As a non-limiting example, medicant(s) can be provided to influence hemostasis, inflammation, macrophages, and / or fibroblasts. When used in conjunction with a surgical stapler, the adjunct(s) can be disposed between and / or on jaws of the stapler, incorporated into a staple cartridge disposed in the jaws, or otherwise placed in proximity to the staples. When staples are deployed, the adjunct(s) can remain at the treatment site with the staples.

An aqueous humor outflow device comprises an arcuate scaffold that extends continuously in a circumferential direction from a first end to a second end of the aqueous humor outflow device and has a cross-sectional area that allows the arcuate scaffold to fit within a conventional aqueous humor outflow pathway of a mammalian eye. The arcuate scaffold comprises a docking station or a port within which to retain an implant device, such as a drug eluting device or a drug delivery device.

The invention relates to drug eluting shape memory foams. Tumorectomy is typically performed to prevent the progression of cancer. However, there is postoperative concern, including the formation of voids that may allow cancer cells to escape at the surgical site, which increases the risk of metastasis. To combat this challenge, embodiments include a polyurethane-based shape memory foam as a tissue void filling device, which can also release an anti-cancer drug. Such foams can be activated at body temperature and become malleable. Such properties may enable the foam to be shaped to precisely seal tissue voids, and then act as a drug eluting device. Based on a pharmaceutical composition having polyvinyl alcohol (PVA), the characteristic of drug release from foam can be varied depending on application.

The application discloses a kind of preparation targeted therapeutic drug elution equipment, it is related to the field of drug preparation, the application includes base, electric control platform, screening groove, collection box, elution tank, water tank, drying groove, screening groove includes piston, piston is installed in the surface of screening groove body, collection box includes flap door, flap door is installed in the surface of screening groove body, elution tank includes motor, motor is installed in the other surface of elution tank body, water tank includes water pump, several water pumps are installed in water tank body inside, drying groove includes electric lifting plate, the other surface of water tank body is equipped with several sliding grooves, and the surface of electric lifting plate is slidably connected with the inside of sliding groove.The application is a kind of preparation targeted therapeutic drug elution equipment by setting screening groove, can be impurity treated to drug raw materials;By setting drying groove, the raw material after elution can be dried and dehydrated.

Systems and methods for treatment of vascular lesions. The system includes a drug-eluting distal portion of a drug-eluting catheter and a balloon of a balloon catheter configured for positioning with a vascular lesion. The method entails securing the drug-eluting distal portion to the inner wall of a blood vessel with the balloon, and delivery of therapeutic agents into the blood vessel wall while the drug-eluting distal portion is held against the wall of the blood vessel by the balloon. The distal infusion portion of the drug infusion catheter is first located within the lesion. After the drug infusion portion is in position, the balloon of the balloon catheter is translated into the lesion and inflated to press the drug-eluting portion into contact with the blood vessel wall and a therapeutic agent is delivered through the drug-eluting portion.

The present disclosure relates to intraocular drug-eluting particulate implants and dry particulate formulations comprising a plurality of drug-eluting particulate implants for use in the treatment of conditions of the eye, wherein the implants are configured to deliver a drug to the eye without a carrier. The present disclosure also relates to methods of treating conditions of the eye by delivering one or more drugs from a drug eluting implant or dry particulate formulation to the anterior chamber, posterior chamber (e.g., ciliary sulcus), iris corneal horn, sclera, cornea, limbus, subconjunctival space, subcapsular space, and vitreous body.

Proposed is a drug-eluting expandable urethral balloon catheter. The drug-eluting expandable urethral balloon catheter includes a tube part inserted into the urethra, a separation prevention part including a first balloon that expands in the bladder according to the inflow of fluid to prevent separation the of tube part and maintain airtightness of the bladder, a drug injection part having a plurality of pores formed so that a drug is injected into the stricture site of the urethra, a urethra expansion part including a second balloon which is positioned on a front end of the drug injection part and inflates or contracts according to the inflow and outflow of fluid, and a branched connection part branched from one side of the tube part to be connected thereto so as to enable fluid to flow in and out of the tube part.

The present disclosure provides a method of preventing blood coagulation, comprising administering an effective amount of a ginsenoside Compound K (CK) to a subject in need. The present disclosure also provides use of a ginsenoside Compound K (CK) in the manufacture a medicament for preventing blood coagulation. Further, the present disclosure provides a drug-eluting percutaneous coronary intervention (PCI), comprising a blood vessel implant, wherein a surface of the blood vessel implant is coated with a first layer comprising ginsenoside Compound K (CK) and a first bioabsorbable polymer, wherein the first bioabsorbable polymer comprises Poly-L-lactic acid (PLLA) and Poly (L-Lactide-co-ε-Caprolactone) (PLCL) in a weight ratio of 60%-80%: 20%-40%.

Drug-eluting device The present invention relates to: (i) a drug delivery device comprising a fibrous material, said fibrous material comprising: (a) a first fibre which comprises: - a first polymeric material comprising a carbon nanoparticle covalently bonded to a polymer; and / or - a first acidic polysaccharide; and / or - a first protein; and (b) a drug, and a method of manufacture thereof, as well as said drug delivery device for use in administering a drug.

DRUG ELUTING OCULAR IMPLANT

A heart valve prosthesis with one or more drug eluting mechanisms embedded in the prosthesis during manufacture.

DRUG ELUTING OCULAR IMPLANT

A gastric retention system comprising one or more retention members comprising: at least one drug eluting component; and at least one laser joint component laser welded to the at least one drug eluting component.

Devices, systems, and methods for treating vascular defects are disclosed herein. According to some embodiments, the present technology includes an intravascular medical device comprising a tubular scaffold with a plurality of interconnected members. The tubular scaffold can be configured to expand from a collapsed state to an expanded state when implanted within a blood vessel. In some embodiments, the medical device further includes a plurality of carriers disposed about the tubular scaffold, each comprising a carrier body and a recess defined by the carrier body. A therapeutic agent may be released from the recesses in vivo, thereby providing a therapeutic effect to a treatment site.

To provide an intraocular drug delivery platform for use with an intraocular lens assembly.SOLUTION: There is provided an intraocular drug delivery platform for use with an intraocular lens assembly. The platform includes a ring, haptics to maintain the ring in position in the capsular bag, compartments on the anterior surface of the ring for accommodating a drug-eluting matrix or other drug mass, and a skirt extending posteriorly from the posterior surface of the ring to constrain movement, including lateral or inferior / superior movement, of the intraocular lens relative to the ring.SELECTED DRAWING: Figure 3

DRUG ELUTING OCULAR IMPLANT

Disclosed herein is a biomaterial and a method of use thereof for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.

The present disclosure relates to intraocular drug-eluting microparticle implants and dry microparticle formulations comprising a plurality of drug-eluting microparticle implants for treating ocular conditions, wherein the implants are configured to deliver a drug to the eye without a carrier. The present disclosure also relates to methods of treating ocular conditions by delivering one or more drugs or dry microparticle formulations from the drug-eluting implants to the anterior chamber, posterior chamber (e.g., sulcus), iridocorneal angle, sclera, cornea, limbus, subconjunctival space, sub-Tenon space, and vitreous.